Autres langues GENFIT Börse Stuttgart

Actions

XUP

FR0004163111

Recherche biotechnologique et médicale

Temps réel estimé Tradegate 14:18:25 28/09/2026			Varia. 5j.	Varia. 1 janv.
9,645 ^EUR	+8,25%		-10,17%	+88,82%

25/09	Agenda Zonebourse des résultats de sociétés : semaine du 28 septembre au 2 octobre 2026
15/09	Bourse : AXA fixe ses objectifs 2029, Airbus confiant, Renault promu par Moody's

Autres langues

15/09	French and Benelux stocks-Factors to watch on September 15
15/09	France's Genfit Plans Phase 2a Trial of Liver Failure Treatment
14/09	GENFIT Advances Nangibotide in Phase 2 Clinical Investigation in ACLF
14/09	Genfit Advances Nangibotide into Phase 2 Clinical Investigation in Acute-On-Chronic Liver Failure
14/09	GENFIT to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris
11/09	Inflation bringt die Wall Street in die Zwickmühle
11/09	Afternoon Meeting: La inflación acorrala a Wall Street
11/09	Inflation Has Wall Street Cornered
11/09	A very bad trip for markets?
11/09	GENFIT to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris
11/09	French and Benelux stocks-Factors to watch on September 11
10/09	Euronext includes Genfit, Inventiva in SBF120 index; Interparfums, Verallia excluded
10/09	GENFIT to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
09/09	GENFIT Highlights Long-Term Commercial Opportunity for its MASH Diagnostics Technology
04/09	GENFIT to Host Virtual KOL Event Focused on MASH Diagnostics on September 9, 2026
03/09	GENFIT to Host Virtual KOL Event Focused on MASH Diagnostics on September 9, 2026
03/08	GENFIT : Answers its Investors – Episode #3 - August 3, 2026
08/07	Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
03/07	Genfit's Liver Disease Blood Test Approved for US Medicare Reimbursement
02/07	GENFIT Announces U.S. Medicare Coverage and Future Reimbursement for NASHnext®, a Non-Invasive Diagnostic Technology to Identify Patients with At-Risk MASH
02/07	Genfit Announces U.S. Medicare Coverage and Future Reimbursement for Nashnext, A Non-Invasive Diagnostic Technology to Identify Patients with At-Risk Mash
29/06	Saudi Food and Drug Authority Approves Registration of Aikervo (Elafibranor) for Treatment of Primary Biliary Cholangitis
24/06	Genfit's Investigative Treatment for Bile Duct Cancer Shows Positive Results in Phase 1b Study
23/06	GENFIT Reports Positive Phase 1B Data for GNS561 in Combination Therapy in Heavily Pretreated Patients with Cholangiocarcinoma
23/06	GENFIT: Positive Phase 1b Data with GNS561 in Combination Therapy in Heavily Pretreated Patients with Cholangiocarcinoma